Article and Video CATEGORIES
People have said to me that a name like Jack West sounds like a good TV name, so I suppose it was only a matter of time before I found my way to the small screen. Yikes!
(click on image to enlarge)
This coming Saturday (August 14th), I'll be part of a team of three on an expert panel covering many aspects of lung cancer on a program on Discovery Channel called Discovery Channel CME: Individualized Therapy for Non-Small Cell Lung Cancer. It airs at 8 AM and repeats again at 8 AM on August 21st and 28th.
Though it's continuing medical education (CME) and is ostensibly targeted for physicians, we provide a very broad coverage of the field that many people here may find helpful, if not even a bit basic. My co-panelists are Dr. Mark Socinski (Univ. of North Carolina at Chapel Hill), who recently did a terrific webinar program on maintenance therapy for advanced NSCLC, and Dr. Jyoti Patel (Northwestern Univ.), who is a longtime friend and now leads the very important POINT BREAK Phase III trial.
My suggestion was to have the experts voted off of the panel one by one as the program progressed, just to spice things up and add some suspense a la Survivor. Surprisingly, they didn't go for that.
So, hey --- it's a start. It's 8 AM, so if you're interested, you can always TiVo it...
Be glad I spared you the photo of me with the make-up artist.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…